Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

5(83.3%)

Phase 3

1(16.7%)

6Total

Phase 2(5)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06999603Phase 2Recruiting

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

Role: lead

NCT04518410Phase 2Completed

ACTIV-2: A Study for Outpatients With COVID-19

Role: collaborator

NCT04732949Phase 3Completed

Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19

Role: lead

NCT04385095Phase 2Completed

Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection

Role: lead

NCT03570359Phase 2Completed

A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza

Role: lead

NCT05207293Completed

Pilot Test of COVID-19 Related Clinical Outcome Assessment Methodology and Qualitative Evidence of Content Validity

Role: lead

NCT01126177Phase 2Completed

Comparing Efficacy and Safety of Inhaled SNG001 to Placebo

Role: lead

All 7 trials loaded